PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Status:
RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), N-803 (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer.
The names of the therapies involved in this study are:
* PD-L1 t-haNK cell therapy (a NK cell therapy infusion)
* N-803 (a type of recombinant human superagonist)
* Cetuximab (a type of antibody)